Treatment group

TOF ratio at or before extubation, n (%)

Sugammadex 4.0 mg/kg (n=50a)

Neostigmine 50 μg/kg (n=43a)


48 (96.0)b

17 (39.5)b,c

>0.8 to <0.9

1 (2.0)

6 (14.0)

>0.7 to ≤0.8

0 (0.0)

5 (11.6)

>0.6 to ≤0.7

0 (0.0)

5 (11.6)


1 (2.0)

10 (23.3)

aPatients with data available: In total, three patients (one sugammadex and two neostigmine) were excluded from the table because monitoring was stopped before extubation due to the patient moving or waking up. The last recorded TOF ratios were 0.8 in the sugammadex patient and 0.5 and 0.6, respectively, in the neostigmine patients, but it cannot be discounted that these patients would have recovered to a TOF ratio of ≥0.9 by the time of extubation. In addition, one neostigmine patient was not included because the TOF trace was considered to be unreliable; bIncludes seven patients in the sugammadex group and five patients in the neostigmine group in whom the monitor was switched off before extubation because the patient was already awake or moving but who had reached a TOF ratio of ≥0.9; cFisher’s exact test, P=<0.0001 for sugammadex versus neostigmine
Table 2: Train-of-four (TOF) ratios at or before tracheal extubation by treatment group (intent-to-treat group, n=97).